Sight Sciences, Inc. (SGHT) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Sight Sciences reported revenue of $77.4M, down 3.1% from $79.9M the year before. Net income was -$38.4M (a -49.7% net margin), or -$0.74 per diluted share. Gross margin was 86.2% and operating margin was -48.0%. Operating activities generated -$29.7M of cash, leaving -$29.9M of free cash flow. At fiscal year end, Sight Sciences held $115.3M in total assets against $51.4M in total liabilities, including $92.0M of cash and equivalents.
Open the full interactive Sight Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Sight Sciences Key Stats
| Share Price | $8.39 |
|---|---|
| Market Cap | $457.3M |
| Revenue YoY Growth | -3.1% |
| 52-Week Range | $3.26 – $9.36 |
| Shares Outstanding | 54.5 million (basic, 2026 Q2) |
Sight Sciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Cost of Goods Sold | $8.6M | $12.4M | $11.9M | $11.6M | $10.7M |
| Gross Profit | $40.3M | $59.0M | $69.2M | $68.3M | $66.7M |
| Operating Income | -$51.5M | -$84.0M | -$57.3M | -$50.5M | -$37.1M |
| Pre-Tax Income | -$62.8M | -$86.2M | -$55.4M | -$51.3M | -$38.4M |
| Income Tax | $188,000 | $47,000 | $110,000 | $236,000 | $10,000 |
| Net Income | -$63.0M | -$86.2M | -$55.5M | -$51.5M | -$38.4M |
| Diluted EPS | -$2.36 | -$1.80 | -$1.14 | -$1.03 | -$0.74 |
Sight Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $19.9M | $20.4M | $19.7M | $23.4M |
| Net Income | -$8.2M | -$4.2M | -$13.0M | -$4.4M |
| Diluted EPS | -$0.16 | -$0.08 | -$0.24 | -$0.08 |
Sight Sciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $260.7M | $185.0M | $138.1M | $120.4M | $92.0M |
| Current Assets | $277.0M | $209.7M | $162.9M | $139.8M | $112.7M |
| Total Assets | $280.2M | $213.1M | $166.7M | $142.8M | $115.3M |
| Current Liabilities | $13.5M | $17.8M | $12.3M | $15.5M | $11.0M |
| Total Long-Term Debt | $35.0M | $35.0M | $33.9M | $40.0M | $42.4M |
| Total Liabilities | $48.1M | $53.0M | $46.4M | $55.3M | $51.4M |
| Shareholders' Equity | $232.1M | $160.1M | $120.2M | $87.5M | $63.9M |
Sight Sciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$52.5M | -$76.0M | -$47.2M | -$22.4M | -$29.7M |
| Cash From Investing | -$813,000 | -$970,000 | -$791,000 | -$385,000 | -$224,000 |
| Cash From Financing | $252.5M | $1.2M | $1.1M | $5.0M | $1.8M |
| Free Cash Flow | -$53.4M | -$76.9M | -$48.0M | -$22.7M | -$29.9M |
Figures from Sight Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sight Sciences financials page for every line item.
Sight Sciences Company Profile
| Ticker | SGHT |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Menlo Park, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001531177 |
Frequently Asked Questions
What was Sight Sciences' revenue in fiscal 2025?
Sight Sciences (SGHT) reported revenue of $77.4M for fiscal 2025.
What is Sight Sciences' annual revenue history?
Sight Sciences' annual revenue by fiscal year: 2021: $49.0M; 2022: $71.3M; 2023: $81.1M; 2024: $79.9M; 2025: $77.4M.
What was Sight Sciences' net income in fiscal 2025?
Sight Sciences reported net income of -$38.4M for fiscal 2025.
What was Sight Sciences' earnings per share (EPS) in fiscal 2025?
Sight Sciences' diluted EPS was -$0.74 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Sight Sciences generate in fiscal 2025?
Sight Sciences generated -$29.9M of free cash flow in fiscal 2025.
What was Sight Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Sight Sciences reported revenue of $23.4M.
How much debt does Sight Sciences have?
Sight Sciences reported $42.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Sight Sciences are outstanding?
Sight Sciences reported a weighted average of 54.5 million basic shares outstanding in 2026 Q2.
What is Sight Sciences' market cap?
Based on its latest closing price, Sight Sciences (SGHT) has a market capitalization of about $457.3M.
When does Sight Sciences' fiscal year end?
Sight Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is Sight Sciences headquartered?
Sight Sciences lists its business address in Menlo Park, California in its SEC filings.
Sight Sciences Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →